Pancreatic cancer research identifies genetic factors in tumor aggression

Recent advancements in pancreatic cancer research are offering new insights into treatment and disease aggression. Innovative therapies are targeting RAS mutations, which are present in over 90% of cases, and exploring the role of the microbiome to improve survival rates for pancreatic ductal adenocarcinoma.

A study coordinated by Luigi Laghi at the University of Parma, published in ‘Clinical Cancer Research’, has identified the H63D genetic variant of the HFE gene as a key factor in tumor behavior. The research highlights a clinical paradox: while the H63D variant may lead to earlier diagnoses and more opportunities for surgical intervention, it is also linked to more rapid recurrences and reduced post-operative survival.

This multidisciplinary research was supported by AIRC and conducted through the Molecular Gastroenterology Laboratory of the IRCCS Humanitas Clinical Institute, in collaboration with the University of Parma and the University of Turin.